You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

426 Results
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Apr 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Aug 2024
Drug
Other Name(s): Alunbrig®
Jul 2024
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: N/A
Version: 1
Nov 2018
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    brigatinib - For the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer according to clinical criteria
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Neoadjuvant
Jan 2024
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Oct 2024
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018
Guidelines and Advice
Status: Current
ID: N/A
Version: 1
Mar 2018

Pages